Sean Mason | March 29, 2016 | SmallCapPower
A potential cancer treatment breakthrough sparked much speculation Tuesday, while financial questions weakened a healthcare name. Here’s some small stocks making big moves on Tuesday, March 29, 2016 (as of 4 pm EST):
BriaCell Therapeutics Corp. (TSXV: BCT) shares powered 177% higher to $0.36 on Tuesday after the immuno-oncology biotechnology company announced that it has discovered a gene signature potentially explaining why its BriaVax cancer vaccine was exceptionally efficacious in a clinical trial subject with Stage IV breast cancer.
As well, shares of Concordia Healthcare Corp. (TSX: CXR) slipped 9% to $30.10 as the international pharmaceutical company focused on legacy pharmaceutical products and orphan drugs said it is providing information to correct inaccuracies and misstatements that appeared in a recent media report concerning its 2015 audited financial results. The media report, citing an unnamed source, attributes a claim from a research provider that Concordia’s auditor, PricewaterhouseCoopers LLP is `looking closely at 4Q’.
Lithium Americas Corp. (TSX: WLC), meanwhile, reported that it has entered into a definitive agreement with Sociedad Química y Minera de Chile S.A. (NYSE: SQM) for a 50/50 joint venture on the Cauchari-Olaroz lithium project in Argentina. Lithium Americas stock eased 2% to $0.465 following the announcement.
In addition, shares of Sirios Resources Inc. (TSXV: SOI) jumped 12% to $0.235 after the gold project developer released partial assay results from Drill Hole #52, which included 12.08 g/t gold over 20.3 metres.
Finally, Kootenay Silver Inc. (TSXV: KTN) shares rose 4% to $0.275 after the junior explorer announced that it has signed an agreement with Coeur Capital, Inc. to acquire its 2.5% net smelter return royalty on future production from Northair Silver Corp.’s La Cigarra project in Mexico. Kootenay is in the process of acquiring Northair Silver.
Hi, did you know SmallCapPower accepts blog submissions? You can contact me here
DISCLAIMER
The Content contained on this page (including any facts, views, opinions, recommendations, description of, or references to, products or securities) made available by SmallCapPower/Ubika Research is for information purposes only and is not tailored to the needs or circumstances of any particular person. Any mention of a particular security is merely a general discussion of the merits and risks associated there with and is not to be used or construed as an offer to sell, a solicitation of an offer to buy, or an endorsement, recommendation, or sponsorship of any entity or security by SmallCapPower/Ubika Research. The Reader should apply his/her own judgment in making any use of any Content, including, without limitation, the use of any information contained therein as the basis for any conclusions. The Reader bears responsibility for his/her own investment research and decisions. Before making any investment decision, it is strongly recommended that you seek outside advice from a qualified investment advisor. SmallCapPower/Ubika Research does not provide or guarantee any financial, legal, tax, or accounting advice or advice regarding the suitability, profitability, or potential value of any particular investment, security, or information source.
